Analysis

NanoSpheRx's innovative business model is to secure as many Imprex SFL evaluation licenses as possible to as many biopharma labs as possible, bringing in both near-term annual license revenues, and longer-term royalty revenues when a biopharma company integrates Imprex SFL into their manufacturing process.

NanoSpheRx's Imprex SFL technologies solve most of the stability, delivery and patent life challenges facing the biopharma industry, including aggregation and degradation that lead to: restricted shelf live; restricted distribution and storage conditions, preventing sale to much of the third world; frequent recalls due to improper handling and potency losses; and potential toxicity from improper storage.

NanoSpheRx's Imprex SFL technology supports meritorious patent life extension and allows its licensees to leverage valuable inventories.

Proprietary NanoSpheRx technology assets are employed to reformulate and functionally enhance Licensees' existing therapeutics and eliminate considerable retooling, product re-development and raw materials costs while significantly reducing time-to-market deadlines.

Patent Pending NanoSpheRx technologies can also create new product viability and recapture lost market opportunities for Licensees' shelved unstable biopharma drug target assets. Key Imprex SFL technology platforms are primed to produce multiple revenue streams, create substantial new profitable market opportunities and to generate bottom-line savings for our corporate Licensees, while rewarding our Shareholders.